ATE311864T1 - Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis - Google Patents
Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosisInfo
- Publication number
- ATE311864T1 ATE311864T1 AT00202287T AT00202287T ATE311864T1 AT E311864 T1 ATE311864 T1 AT E311864T1 AT 00202287 T AT00202287 T AT 00202287T AT 00202287 T AT00202287 T AT 00202287T AT E311864 T1 ATE311864 T1 AT E311864T1
- Authority
- AT
- Austria
- Prior art keywords
- groups
- pharmaceutically acceptable
- amyloidosis
- propane
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Psychiatry (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3784493A | 1993-03-29 | 1993-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE311864T1 true ATE311864T1 (de) | 2005-12-15 |
Family
ID=21896688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00202287T ATE311864T1 (de) | 1993-03-29 | 1994-03-29 | Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis |
Country Status (8)
Country | Link |
---|---|
EP (3) | EP1060750B1 (de) |
JP (2) | JP3666818B2 (de) |
AT (1) | ATE311864T1 (de) |
CA (1) | CA2159326C (de) |
DE (1) | DE69434571T2 (de) |
DK (1) | DK1060750T3 (de) |
ES (1) | ES2251935T3 (de) |
WO (1) | WO1994022437A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
US20040208875A1 (en) | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
WO1997026919A2 (en) * | 1996-01-24 | 1997-07-31 | Warner-Lambert Company | Method of imaging amyloid deposits |
NZ550116A (en) * | 1997-08-18 | 2008-03-28 | Neurochem Int Ltd | Phosphono-carboxylate compounds for treating amyloidosis |
CA2320224C (en) * | 1998-02-11 | 2008-08-12 | Neurochem, Inc. | Method for modulating macrophage activation |
US6329356B1 (en) | 1998-04-10 | 2001-12-11 | Neurochem, Inc. | Phosphono-carboxylate compounds for treating amyloidosis |
JP2002515429A (ja) * | 1998-05-15 | 2002-05-28 | ネウロケム、インク | ニューロン細胞死を調節する方法 |
AU2006203051C1 (en) * | 1998-05-15 | 2009-01-22 | Bhi Limited Partnership | Use of amyloid inhibitors for modulating neuronal cell death |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6310073B1 (en) | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
AU2005203635B2 (en) * | 1999-05-24 | 2008-08-07 | Bellus Health (International) Limited | Methods and compounds for inhibiting amyloid deposits |
EP1237547A2 (de) * | 1999-07-09 | 2002-09-11 | Isis Innovation Limited | Verbindungen zur krankheitshemmung und zur bereitung von zellen zur transplantation |
KR20090016517A (ko) * | 1999-12-23 | 2009-02-13 | 벨루스 헬스 (인터내셔널) 리미티드 | 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법 |
ES2284895T3 (es) * | 2001-08-08 | 2007-11-16 | Pentraxin Therapeutics Limited | Agente terapeutico para la eliminacion de una poblacion de proteinas no deseadas del plasma. |
US20060135403A1 (en) * | 2002-12-24 | 2006-06-22 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
CA2592320C (en) | 2004-12-22 | 2015-11-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US20060252819A1 (en) * | 2005-04-07 | 2006-11-09 | Astrum Therapeutics Pty Ltd | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
TW200716088A (en) | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
ES2352801T3 (es) | 2005-12-22 | 2011-02-23 | Kiacta Sàrl | Tratamiento de nefropatía diabética. |
CA2666246C (en) | 2006-10-12 | 2013-12-31 | Bellus Health (International) Limited | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
JP2010513219A (ja) * | 2006-12-22 | 2010-04-30 | ベラス ヘルス (インターナショナル) リミテッド | 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療 |
SG10201600910YA (en) | 2009-08-10 | 2016-03-30 | Bhi Ltd Partnership | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid |
CN108623501B (zh) | 2017-03-21 | 2022-04-19 | 润佳(苏州)医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸衍生物及其用途 |
WO2020172698A1 (en) * | 2019-02-25 | 2020-09-03 | The Australian National University | Compounds for treating and preventing net associated complications |
WO2023212289A1 (en) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2437834A1 (fr) * | 1978-10-04 | 1980-04-30 | Lejeune Jerome | Compositions pharmaceutiques a base de l-serine ou de glycine |
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
AU1790988A (en) * | 1987-05-19 | 1988-12-21 | Baylor College Of Medicine | Phosphoethanolamine for treatment of alzheimer's disease |
IT1205042B (it) * | 1987-05-28 | 1989-03-10 | Crinos Industria Farmaco | Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer |
JPH01171638A (ja) * | 1987-12-25 | 1989-07-06 | Kanegafuchi Chem Ind Co Ltd | 血清アミロイドa蛋白用吸着体 |
JP2587842B2 (ja) * | 1987-12-09 | 1997-03-05 | 株式会社ニチレイ | 神経疾患治療・予防剤 |
DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
ATE87918T1 (de) * | 1988-02-19 | 1993-04-15 | Lilly Co Eli | Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren. |
JPH0627072B2 (ja) * | 1988-09-13 | 1994-04-13 | 呉羽化学工業株式会社 | アミノ安息香酸誘導体を有効成分とする生体内抗酸化機構調節剤 |
JPH0667472B2 (ja) * | 1988-11-28 | 1994-08-31 | 鐘淵化学工業株式会社 | 血清アミロイドp蛋白用吸着体 |
US5061721A (en) * | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
DE4004978A1 (de) * | 1990-02-19 | 1991-08-22 | Nmi Naturwissenschaftl U Mediz | Praeventive therapie fuer morbus alzheimer |
US5242932A (en) * | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
US5137873A (en) * | 1990-07-27 | 1992-08-11 | The Children's Medical Center Corporation | Substance p and tachykinin agonists for treatment of alzheimer's disease |
CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
US5705401A (en) * | 1991-11-12 | 1998-01-06 | The University Of Melbourne | Method of assaying for alzheimer's disease |
US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
-
1994
- 1994-03-29 EP EP00202287A patent/EP1060750B1/de not_active Expired - Lifetime
- 1994-03-29 EP EP05022113A patent/EP1614416A3/de not_active Withdrawn
- 1994-03-29 ES ES00202287T patent/ES2251935T3/es not_active Expired - Lifetime
- 1994-03-29 CA CA002159326A patent/CA2159326C/en not_active Expired - Lifetime
- 1994-03-29 JP JP52148594A patent/JP3666818B2/ja not_active Expired - Lifetime
- 1994-03-29 DE DE69434571T patent/DE69434571T2/de not_active Expired - Lifetime
- 1994-03-29 EP EP94909883A patent/EP0691844A1/de not_active Withdrawn
- 1994-03-29 WO PCT/CA1994/000160 patent/WO1994022437A2/en not_active Application Discontinuation
- 1994-03-29 AT AT00202287T patent/ATE311864T1/de active
- 1994-03-29 DK DK00202287T patent/DK1060750T3/da active
-
2004
- 2004-03-30 JP JP2004098346A patent/JP4187072B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1994022437A2 (en) | 1994-10-13 |
JP2004189757A (ja) | 2004-07-08 |
EP1060750A3 (de) | 2003-03-26 |
WO1994022437A3 (en) | 1995-02-09 |
ES2251935T3 (es) | 2006-05-16 |
EP0691844A1 (de) | 1996-01-17 |
JP3666818B2 (ja) | 2005-06-29 |
DE69434571T2 (de) | 2006-08-03 |
DE69434571D1 (de) | 2006-01-12 |
EP1060750A2 (de) | 2000-12-20 |
CA2159326A1 (en) | 1994-10-13 |
DK1060750T3 (da) | 2006-01-09 |
CA2159326C (en) | 2000-05-30 |
EP1614416A3 (de) | 2009-07-01 |
JPH08508260A (ja) | 1996-09-03 |
EP1060750B1 (de) | 2005-12-07 |
EP1614416A2 (de) | 2006-01-11 |
JP4187072B2 (ja) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE311864T1 (de) | Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis | |
DE69635271D1 (de) | Verfahren zu behandlung von amyloidosis | |
EA199800682A1 (ru) | Производные циклической аминокислоты или их фармацевтически приемлемые соли, фармацевтическая композиция и способ лечения депрессии, состояний паники, страха и болевых ощущений | |
FI953467A (fi) | Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja menetelmä niiden valmistamiseksi | |
TR199901132T2 (xx) | N-(aril/heteoaril) amino asit t�revleri, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. | |
NO172388C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-aminokinolin-derivater | |
JPH02250895A (ja) | 神経調節ペプチド | |
KR950032275A (ko) | 시클로펩티드 유도체 및 이의 제조방법 | |
NO871295D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater. | |
FI102759B1 (fi) | Menetelmä terapeuttisesti aktiivisten nona- ja dekapeptidien valmistamiseksi | |
NO870049L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater. | |
NO863373D0 (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater. | |
RU96109375A (ru) | Антитромботические азациклоалкилалканоилпептиды и псевдопептиды | |
DE69419954T2 (de) | Arzneimittel zur Behandlung von Hauterkrankungen | |
NO894720D0 (no) | Farmasoeytisk aktivt protein. | |
CA2290739A1 (en) | New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy | |
NO913644D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater. | |
ES421854A1 (es) | Procedimiento para la preparacion de cloruro de lisino-cal-cio. | |
DE3586752D1 (de) | Verfahren zur herstellung wundheilungsfoerdernder praeparationen und solche praeparationen. | |
KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 | |
RU99101827A (ru) | Фармацевтическая композиция для лечения вирусных заболеваний | |
RU95117518A (ru) | Способ лечения аденоидита | |
CA2127275A1 (en) | Pharmaceutical pentapeptide compositions and methods of use thereof | |
RU93005233A (ru) | Гетероциклические соединения, способ их получения, фармацевтический препарат и способ лечения возбуждаемых аминокислотой рецепторов, методы их изготовления | |
HUP9601528A2 (hu) | Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1060750 Country of ref document: EP |